STAT
AUGUST 10, 2024
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
EMCrit Project
AUGUST 10, 2024
Penetrating Neck Trauma and how to leave the zone EMCrit Project by Scott Weingart, MD FCCM.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
AUGUST 10, 2024
Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.
Drug Patent Watch
AUGUST 10, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Pharmacy Times
AUGUST 10, 2024
The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
The Honest Apothecary
AUGUST 10, 2024
“Yep, son, we have met the enemy, and he is us.” – Walt Kelly The line above comes from “Pogo”, the humble and contemplative opossum from Walt Kelly’s long-running mid-20th century comic strip. Here, Pogo is expressing his acknowledgement and disappointment that from an environmental perspective, we are actually the enemy.
Express Pharma
AUGUST 10, 2024
Indian biotech startup sector – a rapidly growing business segment – has expanded tremendously in the post-COVID era. The biotech startups aim to develop innovative healthcare products, which have huge potential to make substantial contributions to the Indian economy. During the COVID-19 pandemic, a fast regulatory approval process to meet the urgent medical need benefited the bio-entrepreneurs.
Expert insights. Personalized for you.
255 
Let's personalize your content